Active substance
Diethylstilbestrol
- US FDA 13
- NHS prices 1
- Safety 4
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| STILBESTROL | 0.5MG | tablet, delayed release · oral | TABLICAPS | Discontinued | 30 May 1973 |
| STILBESTROL | 1MG | tablet · oral | TABLICAPS | Discontinued | |
| STILBESTROL | 0.5MG | tablet · oral | TABLICAPS | Discontinued | |
| STILBESTROL | 1MG | tablet, delayed release · oral | TABLICAPS | Discontinued | |
| STILBESTROL | 5MG | tablet · oral | TABLICAPS | Discontinued | |
| STILBESTROL | 5MG | tablet, delayed release · oral | TABLICAPS | Discontinued | |
| DIETHYLSTILBESTROL | 0.1MG; 0.5MG; 1MG; 0.25MG; 5MG | tablet, delayed release · oral | LILLY | Discontinued | |
| DIETHYLSTILBESTROL | 0.1MG; 0.5MG | suppository · vaginal | LILLY | Discontinued | |
| DIETHYLSTILBESTROL | 0.1MG; 0.5MG; 1MG; 5MG | tablet · oral | LILLY | Discontinued | |
| STILBESTROL | 0.1MG; 0.5MG | suppository · vaginal | BRISTOL MYERS SQUIBB | Discontinued | |
| STILBESTROL | 0.2MG/ML; 0.5MG/ML; 1MG/ML; 5MG/ML | injectable · injection | BRISTOL MYERS SQUIBB | Discontinued | |
| STILBETIN | 0.1MG; 0.5MG; 1MG; 5MG; 0.25MG | tablet · oral | BRISTOL MYERS SQUIBB | Discontinued | |
| STILBETIN | 0.1MG; 0.5MG; 1MG; 5MG | tablet, delayed release · oral | BRISTOL MYERS SQUIBB | Discontinued |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Diethylstilbestrol 1mg tablets | £209.95 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 14 May 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: Yes - EMA PRAC 12 Mar 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No - EMA PRAC 16 Jan 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No - EMA PRAC 3 Oct 2019 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.